Opus Genetics, Inc.: Chief scientific and development officer departs

What happened Opus Genetics, Inc. filed a Current Report on Form 8-K reporting that Ashwath Jayagopal will transition from his role as the company’s Chief Scientific and Development Officer, effective Oct 19, 2026 (the "Separation Date"). The company and Dr. Jayagopal entered into a separation and release agreement that includes a consulting agreement (the "Letter Agreement").

The Letter Agreement provides for a 6-month consulting arrangement under which Dr. Jayagopal will provide transition services as requested by the company and be paid $250 per hour. The filing says Dr. Jayagopal’s outstanding vested options as of the Separation Date will remain exercisable during the consulting arrangement. The Letter Agreement will be filed as an exhibit to the company’s Annual Report on Form 10-K for the fiscal year ended Dec 31, 2026.

Key details

• Separation date: Oct 19, 2026.
• Consulting term: 6-month arrangement for transition services.
• Consulting pay: $250 per hour.
• Vested stock options outstanding as of the Separation Date remain exercisable during the consulting term.

Why it may matter This 8-K reports Item 5.02 (departure of directors or certain officers), which covers the transition from an officer role and the related separation and consulting agreement. The filing describes the terms of the separation and the consulting arrangement but does not explain the reasons for the departure. The filing does not show why the insider traded or why the company acted.